Olivier Jean Bohuon
Plus aucun poste en cours
Fortune : 65 129 $ au 31/05/2024
Profil
Le Dr Olivier Jean Bohuon est un directeur non exécutif indépendant de Takeda Pharmaceutical Co. Ltd, un président de LEO Pharma A/S, un membre du conseil de surveillance de Virbac SA, un président des Laboratoires Majorelle SAS, un président de OJB Conseil SAS, un directeur général et un directeur de Smith & Nephew A/S (Danemark) et un membre de l'Académie nationale de Pharmacie. Il siège au conseil d'administration de Reckitt Benckiser Group Plc, Takeda Pharmaceutical Co., Ltd, Virbac SA, Smith & Nephew A/S (Danemark), Algotherapeutix SAS, Biotech Promise SCA SICAV-SIF et Biotech Promise. Le Dr Bohuon a été précédemment employé en tant que directeur non exécutif indépendant par Smiths Group Plc, directeur non exécutif par Shire Plc, directeur général et administrateur par Smith & Nephew PLC, président et directeur général par Pierre Fabre SA, président par Abbott Pharmaceutical, Inc. et vice-président exécutif des produits pharmaceutiques par Abbott Laboratories, membre de l'Académie des Technologies, premier vice-président des opérations commerciales européennes par GlaxoSmithKline Plc, et directeur du marketing et des ventes par Roussel Uclaf SA. Il a obtenu son MBA à l'école des Hautes tudes Commerciales de Paris et un doctorat à l'Université de Paris Jussieu.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
21/03/2024 | 1 149 ( 0,00% ) | 65 129 $ | 31/05/2024 |
Anciens postes connus de Olivier Jean Bohuon
Sociétés | Poste | Fin |
---|---|---|
Majorelle Topco Ltd. | Directeur/Membre du Conseil | 05/05/2024 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Directeur/Membre du Conseil | 05/05/2024 |
Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Consultant / Advisor | 05/05/2024 |
Laboratoires Majorelle SAS
Laboratoires Majorelle SAS Medical DistributorsDistribution Services Laboratoires Majorelle SAS operates as an independent French pharmaceutical company. Its products include Vitaros, Optilov, Keat range, and Carmex. The company was founded by Guillaume El Glaoui in 2012 and is headquartered in Paris, France. | Président | 05/05/2024 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Fondateur | 05/05/2024 |
Formation de Olivier Jean Bohuon
University of Paris Jussieu | Doctorate Degree |
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 7 |
---|---|
ABBOTT LABORATORIES | Health Technology |
SMITH & NEPHEW PLC | Health Technology |
GSK PLC | Health Technology |
RECKITT BENCKISER GROUP PLC | Consumer Non-Durables |
SMITHS GROUP PLC | Producer Manufacturing |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
VIRBAC | Health Technology |
Entreprise privées | 15 |
---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Health Technology |
Roussel Uclaf SA | Health Technology |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Finance |
Académie des Technologies
Académie des Technologies Academie des Technologies engages in the technology industry. The company was founded in December 2000 and is headquartered in Paris, France. | |
Abbott Pharmaceutical, Inc. | |
Laboratoires Majorelle SAS
Laboratoires Majorelle SAS Medical DistributorsDistribution Services Laboratoires Majorelle SAS operates as an independent French pharmaceutical company. Its products include Vitaros, Optilov, Keat range, and Carmex. The company was founded by Guillaume El Glaoui in 2012 and is headquartered in Paris, France. | Distribution Services |
Académie nationale de Pharmacie | |
Smith & Nephew A/S (Denmark)
Smith & Nephew A/S (Denmark) Medical SpecialtiesHealth Technology Smith & Nephew A/S operates as a is a global medical technology business. It specializes in healthcare, medical supplies, medical devices, wound care, orthopaedic reconstruction and sports medicine. The company was founded by Thomas James Smith in 1856 and is headquartered in Horsholm, Denmark. | Health Technology |
Biotech Promise | Miscellaneous |
OJB Conseil SAS | |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |
Biotech Promise SCA SICAV-SIF | |
Majorelle Topco Ltd. |